1. Home
  2. PAMT vs CRDL Comparison

PAMT vs CRDL Comparison

Compare PAMT & CRDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo PAMT CORP

PAMT

PAMT CORP

HOLD

Current Price

$12.50

Market Cap

275.4M

Sector

Industrials

ML Signal

HOLD

Logo Cardiol Therapeutics Inc.

CRDL

Cardiol Therapeutics Inc.

HOLD

Current Price

$2.27

Market Cap

226.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PAMT
CRDL
Founded
1980
2017
Country
United States
Canada
Employees
N/A
N/A
Industry
Trucking Freight/Courier Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
275.4M
226.6M
IPO Year
1995
2017

Fundamental Metrics

Financial Performance
Metric
PAMT
CRDL
Price
$12.50
$2.27
Analyst Decision
Hold
Strong Buy
Analyst Count
1
2
Target Price
$13.00
$8.50
AVG Volume (30 Days)
15.3K
1.6M
Earning Date
05-12-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$437,838,000.00
N/A
Revenue This Year
$20.12
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.15
N/A
52 Week Low
$7.15
$0.88
52 Week High
$17.75
$2.28

Technical Indicators

Market Signals
Indicator
PAMT
CRDL
Relative Strength Index (RSI) 47.01 72.76
Support Level $10.69 $0.95
Resistance Level $13.04 $2.28
Average True Range (ATR) 0.85 0.15
MACD 0.14 0.01
Stochastic Oscillator 67.26 87.05

Price Performance

Historical Comparison
PAMT
CRDL

About PAMT PAMT CORP

PAMT Corp is a holding company that is engaged in providing truckload dry van carrier services transporting general commodities throughout the continental United States and Mexico, as well as in certain Canadian provinces. Its freight consists of automotive parts, expedited goods, consumer goods, such as general retail store merchandise, and manufactured goods, such as heating and air conditioning units. It has one reportable segment being motor carrier.

About CRDL Cardiol Therapeutics Inc.

Cardiol Therapeutics Inc is a late-stage life sciences company focused on advancing the development of anti-inflammatory and anti-fibrotic therapies for heart disease. Its primary small-molecule candidate, CardiolRx, targets inflammasome pathway activation, which is involved in the development of inflammation and fibrosis in conditions such as pericarditis, myocarditis, and heart failure. The CardiolRx program includes the completed Phase II MAVERIC-Pilot study and the ongoing Phase III MAVERIC trial for the treatment of pericarditis. The ARCHER program evaluated CardiolRx in acute myocarditis through a completed Phase II study. The company is also developing CRD-38, a novel subcutaneous drug formulation for treating inflammatory heart conditions, including heart failure.

Share on Social Networks: